This paper is only available as a PDF. To read, Please Download here.
This double-masked, randomized, placebocontrolled study was conducted in healthy adult male and female volunteers with no clinically relevant baseline electrocardiographic (ECG) abnormalities to assess the cardiac tolerability margin of sparfloxacin (as measured by the effect on QTc interval) under conditions of potential overdose at up to 4 times the usual therapeutic loading dose. The 23 enrolled volunteers received a sequence of single doses of sparfloxacin (400, 800, 1200, and 1600 mg), 1 dose in each of 4 study periods. Six volunteers received placebo during each period. A 14-day washout separated the periods. Serial blood samples and ECG measurements were collected in each period to determine the pharmacokinetic and pharmacodynamic characteristics of sparfloxacin. The area under the concentration-time curve from time zero to infinity (AUC0–∞) exhibited dose proportionality. The maximum plasma concentration (Cmax) after the 1200-and 1600-mg doses was lower than would be expected for a linear dose relationship. This was also the case with the mean increase and mean maximum increase in QTc interval. Increases in the QTc interval correlated well with Cmax but not with AUC0–∞. The time to reach Cmax showed a slight tendency to increase with dose, as did the terminal elimination half-life. Changes in QTc-interval dispersion were similar for both placebo recipients and sparfloxacin-treated volunteers and were of no clinical consequence. At supratherapeutic doses, the extent of sparfloxacin's absorption (AUC0–∞) was dose independent; however, the rate of absorption was dose dependent, with Cmax increasing substantially less than proportionally to the administered dose. This limited the Cmax of sparfloxacin at supratherapeutic doses and thus the increase in QTCc interval. Rechallenge demonstrated that only 2 of 8 subjects had the same degree of QTc-interval prolongation, emphasizing the marked variability in the QTc interval.
- Pharmacokinetic interactions related to the chemical structures of fluoroquinolones.J Antimicrob Chemother. 1996; 37: 41-55
- Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin.RinshoYakuri. 1991; 7: 1639-1684
- Overview of electrocardiographic and cardiovascular safety data for sparfloxacin.J Antimicrob Chemother. 1996; 37: 161-167
- Sparfloxacin: A review of its antimicrobial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.Drugs. 1997; 53: 700-725
- Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin.Chest. 1996; 110: 1499-1506
- Pharmacokinetics of sparfloxacin in human volunteers and patients: A review.J Antimicrob Chemother. 1996; 37: 27-39
- Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.J Clin Pharmacol. 1994; 34: 1071-1076
- Rxar® package insert.Glaxo Wellcome, Inc., Research Triangle Park, NC1999
- Physicians' Desk Reference®.in: Medical Economics Co., Inc., Montvale, NJ1998: 438-445
- Rarfloxacin package insert.Rhône-Poulenc Rorer Pharmaceuticals, Inc., Collegeville, Pa1997
Accepted: April 5, 1999
© 1999 Published by Elsevier Inc.